Navigation Links
Fuse Science Partners With the New England Consulting Group to Advance Technology Licensing Efforts in Pharmaceutical and OTC Categories
Date:8/10/2011

AVENTURA, Fla., Aug. 10, 2011 /PRNewswire/ -- Double Eagle Holdings, Ltd. (OTCQB: DEGH), announced today that it has retained The New England Consulting Group (NECG) in a strategic partnership to advance licensing efforts for the company's proprietary technology throughout the pharmaceutical and over-the-counter (OTC) markets. Double Eagle Holdings is the parent company of Fuse Science, Inc. (www.fusescience.com), the developer of new, proprietary technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals.

Fuse Science has successfully developed and maintains the rights to sublingual, buccal, and transdermal delivery systems for bioactive agents that can now, for the first time, effectively encapsulate and charge many varying molecules in order to produce complete product formulations which can bypass the gastrointestinal tract and enter the blood stream directly.

"Our proprietary technology effectively penetrates the mucosa and epithelium to achieve complete and enhanced absorption, and it is our firm belief that at this moment we can deliver a wide range of product formulations via these delivery systems," said Rob Davidson, Chief Scientific Officer at Fuse Science.

"We have high confidence that our proprietary technology can effectively produce aspirin, OTC medications, energy and electrolyte products, sleep aids, appetite suppressants, pharmaceutical medications including enhancement products like Viagra and Cialis, along with vitamins and complex nutrition products – it is easy to understand that we must aggressively advance our licensing efforts with the leading companies in these categories," said Brian Tuffin, President and Chief Operating Officer. "Our deliberate strategy is to open licensing discussions with the number 1 and 2 brands in each respective category, and our partnership with The New England Consulting Group is a key enabler to accelerate this effort."

Founded in 1981 and headquartered in Westport, CT, The New England Consulting Group (http://www.necg.net/) is a global leader in marketing and management consulting, providing strategic counsel and business development services to the world's largest and most successful companies.

"After thoroughly reviewing the Fuse Science platform, we believe this proprietary technology will change the face of many major categories of products that we consume each day," said Gaurav Kapoor, Managing Partner and Principal at NECG. "Through our extensive work with the leaders of industry in these categories, we are confident that this partnership has the ability to open new doors of development and consumer satisfaction and we are excited to be working with the Fuse Science team."

About Double Eagle Holdings
Double Eagle Holdings (OTCQB: DEGH.pk) is the holding company of Fuse Science, Inc., an innovative consumer products company based in Aventura, Florida. Fuse Science is the developer of patent-pending conveyance technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals, delivering their benefits faster and more effectively than ever before. Information about Fuse Science is available online at www.fusescience.com or by calling 305-503-FUSE (3873).

Safe Harbor Statement: Certain statements and information included in this release may constitute "forward-looking statements" as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management's projections, estimates and expectations is contained in the company's SEC filings. The company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.


'/>"/>
SOURCE Double Eagle Holdings, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
4. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
8. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
9. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
10. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... MENLO PARK, Calif. , Oct. 11, 2017 /PRNewswire/ ... a national scientific team that developed an innovative way ... and quantity of the delivery of new drugs. ... the 2017 Fall Clinical Dermatology Conference will show how ... Massachusetts General Hospital, Harvard Medical School used a suite ...
(Date:10/11/2017)... FRISCO, Texas , Oct. 11, 2017 /PRNewswire/ ... healthcare services, has amplified its effort during National ... patients about hereditary cancer risks. ... Journal of Clinical Oncology calculated that more than ... to have inherited mutations in BRCA1 or BRCA2 and ...
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... Ky. (PRWEB) , ... October 13, 2017 , ... The ... MPH to become its next President and Chief Executive Officer, succeeding Dr. James C. ... CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of ...
(Date:10/13/2017)... Ill. (PRWEB) , ... October ... ... Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer ... healthcare professionals on guideline updates for the primary prevention of cardiovascular diseases ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed ... geared towards children of all ages; it is a non-competitive, non-timed event, which is ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
Breaking Medicine News(10 mins):